UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050583
Receipt number R000057617
Scientific Title Study for the efficacy and safety of oral semaglutide in subjects with type 2 diabetes -retrospective observation trial
Date of disclosure of the study information 2023/03/14
Last modified on 2023/03/14 23:49:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study for the efficacy and safety of oral semaglutide in subjects with type 2 diabetes

Acronym

Study for the usefulness and safety of oral semaglutide

Scientific Title

Study for the efficacy and safety of oral semaglutide in subjects with type 2 diabetes -retrospective observation trial

Scientific Title:Acronym

Study for the usefulness and safety of oral semaglutide

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Medicine in general Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the changes in glycemic control and body weight before and after semaglutide treatment in addition to safety analysis.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

1) The changes in HbA1c before and after semaglutide treatment
2) The safety of semaglutide especially regarding gastrointestinal symptoms and hypoglycemia

Key secondary outcomes

1) The change in body weight
2) The changes in plasma glucose, systolic/diastolic blood pressure, pulse rate, lipid metabolism, liver function, kidney function, proteinuria, and microalbuminuria after 6 months semaglutide treatment
3) The changes in drugs for diabetes, dyslipidemia, and hypertension after 6 months semaglutide treatment
4) Adverse effects
5) Patient background
6) The factors associated with improvement of HbA1c and body weight
7) Effects of continuation or discontinuation of anti-hyperglycemic agents other than semaglutide
8) Effects of medications for the comorbidities on body weight after semaglutide treatment


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Subjects with type 2 diabetes who were newly treated with oral-semaglutide between 2/5/2021 to 12/31/2022

Key exclusion criteria

1) Subjects for whom administration of oral semaglutide is contraindicated in the package insert (a history of hypersensitivity to the components of this drug, hyperglycemic emergencies such as diabetic ketoacidosis, severe infections)
2) Subjects who are inadequate to enter this study due to the other reasons by physician's judgments

Target sample size

500


Research contact person

Name of lead principal investigator

1st name Hiroshi
Middle name
Last name Nomoto

Organization

Hokkaido University Hospital

Division name

Department of diabetology and endocrinology

Zip code

060-0811

Address

North 15 West 7, Kita-ku, Sapporo, Hokkaido, Japan

TEL

011-706-5915

Email

hnomoto@med.hokudai.ac.jp


Public contact

Name of contact person

1st name Hiroshi
Middle name
Last name Nomoto

Organization

Hokkaido University Hospital

Division name

Department of diabetology and endocrinology

Zip code

060-0811

Address

North 15 West 7, Kita-ku, Sapporo, Hokkaido, Japan

TEL

011-706-5915

Homepage URL


Email

hnomoto@med.hokudai.ac.jp


Sponsor or person

Institute

Hokkaido University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Review Board for Life Science and Medical Research, Hokkaido University Hospital

Address

North 14, West 5, Kita-ku, Sapporo, Hokkaido, Japan

Tel

011-706-7636

Email

crjimu@huhp.hokudai.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

北海道大学病院(北海道)、青木内科クリニック(北海道)、栗原内科(北海道)、さっぽろ糖尿病・甲状腺クリニック(北海道)


Other administrative information

Date of disclosure of the study information

2023 Year 03 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2022 Year 10 Month 07 Day

Date of IRB

2022 Year 10 Month 07 Day

Anticipated trial start date

2022 Year 10 Month 19 Day

Last follow-up date

2023 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Laboratory and physical examinations will be compared between week 0 and each examination time point (-6 months, -3 months, -1 month, 3 months, and 6 months after semaglutide administration). Regarding safety, all subjects who started semaglutide will be included. Analysis of other tests will be performed on a Per Protocol Set basis.


Management information

Registered date

2023 Year 03 Month 14 Day

Last modified on

2023 Year 03 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000057617


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name